In
Regents of the Univ. of Cal. v. Broad Inst.,
Inc., No. 2022-1594 (Fed. Cir. May 12, 2025), the
Federal Circuit vacated in part a determination by the Patent Trial
and Appeal Board in a patent interference proceeding, ruling that
the Board incorrectly applied the legal standard for
conception.
Both The Regents of the University of California
("Regents"), and The Broad Institute ("Broad")
asserted priority of invention for patent claims relating to
CRISPR-Cas9 Systems that contain a "single guide" RNA
that edits or cleaves DNA in eukaryotic cells.
The Board awarded Broad priority based on an October 5, 2012,
publication after rejecting Regents' earliest asserted
conception date of March 1, 2012, and reduction to practice date of
August 9, 2012, based on Regents' statements of uncertainty
about whether its experiments would translate to human cells.